New Diagnostic Criteria Narrows the Definition of Parkinson's Disease
The Movement Disorders Society has recently published Clinical Diagnostic Criteria for Parkinson’s disease. These new guidelines allow for the diagnosis of clinically established and clinical probable Parkinson’s disease, which will help reduce errors in clinical trials.
Even though Idiopathic Parkinson's disease is, after Alzheimer's disease, the second-most common neurodegenerative disorder, approximately 5% to 10% of Parkinson's patients are misdiagnosed-and up to 20% of patients diagnosed with Parkinson's later turn out to have different disorders. Seeing a need to update the diagnostic criteria for Parkinson's that have been used in clinical trials for over 20 years, the Movement Disorders Society recently published Clinical Diagnostic Criteria for Parkinson's disease-a new set of guidelines that reflect the medical community's more recent understanding of the condition. For example, in addition to requiring a diagnosis of parkinsonism-that is, bradykinesia (slowness of movement) in conjunction with rigidity, rest tremor, or both-the guidelines include supportive criteria and a red flag list to determine whether or not Parkinson's disease is the cause of the patient's parkinsonism. Together, these guidelines allow for diagnosis of clinically established Parkinson's disease and clinically probable Parkinson's disease-and will help reduce diagnostic errors in clinical trials. Stopping Parkinson's Before it Starts The Movement Disorders Society Research Criteria also defines "prodromal Idiopathic Parkinson's disease," or preclinical Parkinson's-a stage during which patients experience brain tissue pathological changes and may even experience motor or non-motor symptoms, but don't quite meet the diagnostic criteria for Parkinson's disease. More accurate diagnosis of prodromal Parkinson's will allow clinical trials to better assess the effectiveness of newly developed neuroprotective drugs designed to stop or slow the progression of the disease. This new criteria should stimulate new research into earlier stages of Parkinson's, with the ultimate goal of designing clinical trials that can test intervention for disease prevention in individuals at risk of the disease. Tomislav Babic MD, PhD, is Vice President Neuroscience Franchise, Worldwide Clinical Trials www.Worldwide.com. He can be reached at tomislav.babic@worldwide.com.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
